AIDS Res Hum Retroviruses. 2023 Jun 30. doi: 10.1089/AID.2022.0186. Online ahead of print.
ABSTRACT
With the advancement of effective antiretroviral therapy (ART), people with HIV live longer, and many are developing non-AIDS comorbidities. It is important to assess how comorbidities are associated with HIV-related health outcomes, such as viral suppression (VS). The aim of this study was to analyze the association between comorbidity burden, measured using a modified Quan-Charlson Comorbidity Index (QCCI), and VS (viral load result of <200 copies/mL). We hypothesized that an increase in QCCI score, indicating a higher risk for mortality, would correlate with lower likelihood of VS because of the burden of comorbidity treatment, possibly leading to worse antiretroviral adherence. Our analysis included participants from the DC Cohort Longitudinal HIV Study in Washington, D.C. Eligible participants were aged ≥18 years and enrolled in the cohort as of January 1, 2018 (n=2,471). A modified QCCI score, which weighs selected comorbidities (not including HIV/AIDS) and predicts mortality, was calculated using ICD-9/10 codes from electronic health records. Multivariable logistic regressions were used to characterize the association between QCCI composite scores and VS. Participants were predominantly virally suppressed (89.6%), male (73.9%), Non-Hispanic Black (74.7%) and between 18-55 years old (59.3%). The median QCCI score was 1 (range= 1-12, IQR= 0-2), demonstrating predominately low mortality risk. We did not establish a statistically significant association between QCCI score and VS (adjusted odds ratio=1.06, 95% CI 0.96-1.17). Our findings suggest that a higher QCCI score was not associated with lower VS in this population, which may be partly due to the high retention in care among Cohort participants.
PMID:37392022 | DOI:10.1089/AID.2022.0186
